152 related articles for article (PubMed ID: 8791009)
1. Stable expression of the recombinant human VIP1 receptor in clonal Chinese hamster ovary cells: pharmacological, functional and molecular properties.
Gaudin P; Couvineau A; Maoret JJ; Rouyer-Fessard C; Laburthe M
Eur J Pharmacol; 1996 Apr; 302(1-3):207-14. PubMed ID: 8791009
[TBL] [Abstract][Full Text] [Related]
2. Characterization of VIP receptor-effector system antagonists in rat and mouse peritoneal macrophages.
Pozo D; Montilla ML; Guerrero JM; Calvo JR
Eur J Pharmacol; 1997 Mar; 321(3):379-86. PubMed ID: 9085051
[TBL] [Abstract][Full Text] [Related]
3. Properties of the pituitary adenylate cyclase-activating polypeptide I and II receptors, vasoactive intestinal peptide1, and chimeric amino-terminal pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide1 receptors: evidence for multiple receptor states.
Van Rampelbergh J; Gourlet P; De Neef P; Robberecht P; Waelbroeck M
Mol Pharmacol; 1996 Dec; 50(6):1596-604. PubMed ID: 8967982
[TBL] [Abstract][Full Text] [Related]
4. Analogues of VIP, helodermin, and PACAP discriminate between rat and human VIP1 and VIP2 receptors.
Gourlet P; Vandermeers A; Van Rampelbergh J; De Neef P; Cnudde J; Waelbroeck M; Robberecht P
Ann N Y Acad Sci; 1998 Dec; 865():247-52. PubMed ID: 9928018
[TBL] [Abstract][Full Text] [Related]
5. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in turkey cerebral cortex: characterization by [125I]-VIP binding and effects on cyclic AMP synthesis.
Zawilska JB; Niewiadomski P; Nowak JZ
Gen Comp Endocrinol; 2004 Jun; 137(2):187-95. PubMed ID: 15158130
[TBL] [Abstract][Full Text] [Related]
6. Receptors for VIP and PACAP in guinea pig cerebral cortex: effects on cyclic AMP synthesis and characterization by 125I-VIP binding.
Zawilska JB; Dejda A; Niewiadomski P; Gozes I; Nowak JZ
J Mol Neurosci; 2005; 25(3):215-24. PubMed ID: 15800375
[TBL] [Abstract][Full Text] [Related]
7. Vasoactive intestinal peptide receptor regulation of cAMP accumulation and glycogen hydrolysis in the human Ewing's sarcoma cell line WE-68.
Van Valen F; Jürgens H; Winkelmann W; Keck E
Cell Signal; 1989; 1(5):435-46. PubMed ID: 2561912
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a common VIP-PACAP receptor in human small intestinal epithelium.
Salomon R; Couvineau A; Rouyer-Fessard C; Voisin T; Lavallée D; Blais A; Darmoul D; Laburthe M
Am J Physiol; 1993 Feb; 264(2 Pt 1):E294-300. PubMed ID: 8383439
[TBL] [Abstract][Full Text] [Related]
9. In vitro properties of a high affinity selective antagonist of the VIP1 receptor.
Gourlet P; De Neef P; Cnudde J; Waelbroeck M; Robberecht P
Peptides; 1997; 18(10):1555-60. PubMed ID: 9437716
[TBL] [Abstract][Full Text] [Related]
10. Vasoactive intestinal peptide modification at position 22 allows discrimination between receptor subtypes.
Gourlet P; Vandermeers-Piret MC; Rathé J; De Neef P; Cnudde J; Robberecht P; Waelbroeck M
Eur J Pharmacol; 1998 May; 348(1):95-9. PubMed ID: 9650836
[TBL] [Abstract][Full Text] [Related]
11. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate.
Solano RM; Carmena MJ; Carrero I; Cavallaro S; Roman F; Hueso C; Travali S; Lopez-Fraile N; Guijarro LG; Prieto JC
Endocrinology; 1996 Jul; 137(7):2815-22. PubMed ID: 8770902
[TBL] [Abstract][Full Text] [Related]
12. Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor.
Xia M; Sreedharan SP; Bolin DR; Gaufo GO; Goetzl EJ
J Pharmacol Exp Ther; 1997 May; 281(2):629-33. PubMed ID: 9152366
[TBL] [Abstract][Full Text] [Related]
13. Characterization of binding sites for VIP-related peptides and activation of adenylate cyclase in developing pancreas.
Le Meuth V; Farjaudon N; Bawab W; Chastre E; Rosselin G; Guilloteau P; Gespach C
Am J Physiol; 1991 Feb; 260(2 Pt 1):G265-74. PubMed ID: 1847591
[TBL] [Abstract][Full Text] [Related]
14. Vasoactive intestinal peptide receptor antagonists in rat seminal vesicle membranes.
Rodríguez-Pena MS; Guijarro LG; Prieto JC
Eur J Pharmacol; 1991 Nov; 208(3):207-12. PubMed ID: 1663044
[TBL] [Abstract][Full Text] [Related]
15. The pituitary adenylate cyclase activating polypeptide (PACAP I) and VIP (PACAP II VIP1) receptors stimulate inositol phosphate synthesis in transfected CHO cells through interaction with different G proteins.
Van Rampelbergh J; Poloczek P; Françoys I; Delporte C; Winand J; Robberecht P; Waelbroeck M
Biochim Biophys Acta; 1997 Jun; 1357(2):249-55. PubMed ID: 9223629
[TBL] [Abstract][Full Text] [Related]
16. The C-terminus ends of secretin and VIP interact with the N-terminal domains of their receptors.
Gourlet P; Vilardaga JP; De Neef P; Waelbroeck M; Vandermeers A; Robberecht P
Peptides; 1996; 17(5):825-9. PubMed ID: 8844773
[TBL] [Abstract][Full Text] [Related]
17. Properties of the VIP-PACAP type II receptor stably expressed in CHO cells.
Ciccarelli E; Vilardaga JP; De Neef P; Di Paolo E; Waelbroeck M; Bollen A; Robberecht P
Regul Pept; 1994 Dec; 54(2-3):397-407. PubMed ID: 7716273
[TBL] [Abstract][Full Text] [Related]
18. Ac His1 [D-Phe2, K15, R16, L27] VIP (3-7)/GRF (8-27)--a VPAC1 receptor antagonist--is an inverse agonist on two constitutively active truncated VPAC1 receptors.
Vertongen P; Langlet C; Langer I; Gaspard N; Robberecht P
Peptides; 2004 Nov; 25(11):1943-9. PubMed ID: 15501526
[TBL] [Abstract][Full Text] [Related]
19. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in the goose cerebral cortex.
Zawilska JB; Niewiadomski P; Nowak JZ
Pol J Pharmacol; 2004; 56(2):203-11. PubMed ID: 15156071
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology, molecular identification and functional characteristics of vasoactive intestinal peptide receptors in human breast cancer cells.
Gespach C; Bawab W; de Cremoux P; Calvo F
Cancer Res; 1988 Sep; 48(18):5079-83. PubMed ID: 2842044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
